SHR-A1201

• Target :

  EGFR|||Antibody-Drug Conjugates (ADCs)

• Related Pathways :

  Angiogenesis|||Tyrosine Kinase/Adaptors|||Antibody-drug Conjugate/ADC Related|||JAK/STAT signaling

• Bioactivity :

  SHR-A1201 is an antibody-drug conjugate (ADC) targeting HER2. This compound is composed of a humanized anti-HER2 antibody, the linker SMCC, and the cytotoxic payload Mertansine, which is a microtubule inhibitor. SHR-A1201 is utilized in research for HER2-positive breast cancer.

• Smiles :

  [C@@H](OC(=O)[C@H]1N(C(C(C(CC)(C)C)=O)=O)CCCC1)(CCC2=CC(OC)=C(OC)C=C2)C3=CC(NC(CCOCCOCCNC(CCNC(=O)C4=CC(NC(CCl)=O)=CC(C(F)(F)F)=C4)=O)=O)=CC=C3

• Molecular Formula :

  C50H63ClF3N5O12

• Molecular Weight :

  1018.51

• Shipping Conditions :

  Cool pack

• Storage Temperature :

  -20°C